Skip to main navigation Skip to search Skip to main content

Granzyme B-mimetic nanozyme for nanovesicle targeted anticancer applications

Xueyan Hu, Qiqi Liu, Helong Kang, Ming Zhao, Zheng Zhou, Yuanke Li, Weicheng Peng, Tianyi Qi, Ruming Liu, Li Jiao, Jie Zhuang, Yijin Liu*, Stephen Mann*, Xinglu Huang*

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

Abstract

Cytotoxic T lymphocytes play a crucial role in anti-tumour immunity, with granzyme B (GrB) being a decisive factor in this process. Developing a GrB-based delivery system to mimic T cell-based immunotherapy holds promise but remains challenging. Here, we present an artificial metalloenzyme (nanozyme) with GrB-like protease activity capable of inducing caspase-dependent cell apoptosis. The nanozyme is based on the site-specific binding of Pd(II) ions to recombinant human heavy chain apo-ferritin nanocages to generate a binuclear catalytic centre consisting of two Pd atoms with bridging cysteine ligands, monodentate methionine and histidine residues, and two water molecules. We show that encapsulation of the Pd-ferritin complex within membrane-fused lipid nanoparticles comprising surface-displayed single-chain antibodies affords GrB-mimicking nanozyme-based nanovesicles capable of receptor-mediated delivery of the nanozyme into the cytoplasm of tumour cells and induction of caspase-dependent apoptosis. This study provides valuable insights into the construction of nano-delivery systems with artificial GrB activity and presents a promising therapeutic option for solid tumours.
Original languageEnglish
Article number2031
Number of pages16
JournalNature Communications
Volume17
Issue number1
DOIs
Publication statusPublished - 26 Jan 2026

Bibliographical note

Publisher Copyright:
© The Author(s) 2026.

Fingerprint

Dive into the research topics of 'Granzyme B-mimetic nanozyme for nanovesicle targeted anticancer applications'. Together they form a unique fingerprint.

Cite this